Probiotics in irritable bowel syndrome: an immunomodulatory strategy? (Q37054666)

18 August 2017

1 reference

title

Probiotics in irritable bowel syndrome: an immunomodulatory strategy? (English)

1 reference

18 August 2017

0 references

irritable bowel syndrome

1 reference

Eamonn M M Quigley

1

1 reference

18 August 2017

1 December 2007

1 reference

Journal of the American College of Nutrition

18 August 2017

1 reference

18 August 2017

26

1 reference

18 August 2017

6

1 reference

18 August 2017

684S-90S

1 reference

Systematic review: Complementary and alternative medicine in the irritable bowel syndrome

18 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

The use of probiotics in functional bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Modulation of human dendritic cell phenotype and function by probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

DNA from probiotic bacteria modulates murine and human epithelial and immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Abnormal colonic fermentation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Bacteriocins: developing innate immunity for food

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

The role of psychological and biological factors in postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Evolving pathophysiologic models of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Role of functional brain imaging in gastroenterology in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Tegaserod for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07315724.2007.10719648

10.1080/07315724.2007.10719648

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18187434